TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates

Core Insights - TransMedics Group (TMDX) reported a fourth-quarter 2025 earnings per share (EPS) of 57 cents, marking a 200% increase year over year, and exceeding the Zacks Consensus Estimate by 39% [1][6] - The company achieved total revenues of $160.8 million in Q4 2025, reflecting a 32% year-over-year growth, surpassing the Zacks Consensus Estimate by 3.1% [2][6] - For the full year 2025, TransMedics recorded total revenues of $605.5 million, a 37% increase compared to 2024, and anticipates revenues of $727-$757 million for 2026, indicating a growth of 20-25% from 2025 levels [3][11] Revenue Breakdown - In Q4 2025, net product revenues reached $100.4 million, up 34% year over year, driven by strong performance in liver and heart programs [7] - Service revenues totaled $60.4 million, a 29% increase year over year, primarily due to logistics expansion [7] - Transplant Logistics' service revenues for Q4 2025 were $28.6 million, reflecting a 32% year-over-year growth [7] Margin and Profitability - TransMedics' gross profit increased by 29.7% year over year to $93.4 million, with a gross margin of 58%, down 110 basis points [8] - Operating profit for the quarter was $21.3 million, a 146% increase from the prior year, with an operating margin expansion of 600 basis points to 13% [9] Financial Position - At the end of Q4 2025, TransMedics had cash reserves of $488.4 million, up from $466.2 million at the end of Q3 2025, and total long-term debt decreased to $49.6 million from $54.6 million [10] Growth Initiatives - TransMedics is focused on expanding clinical indications, geographic reach, and next-generation technology across its Organ Care System (OCS) platform, with key programs like ENHANCE Heart and DENOVO Lung progressing through enrollment [14][16] - The OCS ENHANCE Heart program aims to enhance heart transplantation methods, while the OCS DENOVO Lung program seeks to revive lung transplantation growth in the U.S. [15][16] - The company is also advancing the OCS Kidney program, targeting a large and underpenetrated kidney transplant market [17] Market Performance - TransMedics shares gained 6.7% in after-market trading following the earnings report and have increased by 28.3% over the last six months, contrasting with a 3.9% decline in the industry [3][12]